Rezolute Inc
Change company Symbol lookup
Select an option...
RZLT Rezolute Inc
LAUR Laureate Education Inc
DUOT Duos Technologies Group Inc
BCLI Brainstorm Cell Therapeutics Inc
EEX Emerald Holding Inc
JPM-L JPMorgan Chase & Co
SBFM Sunshine Biopharma Inc
SEKEY Seiko Epson Corp
PXMD PaxMedica Inc
CDT Conduit Pharmaceuticals Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.

Closing Price
$1.33
Day's Change
-0.09 (-6.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.39
Day's Low
1.30
Volume
(Light)
Volume:
16,442

10-day average volume:
29,369
16,442
  • Prev Close
    1.42
  • Today's Open
    1.37
  • Day's Range
    1.30-1.39
  • Avg Vol (10-day)
    29.4K
  • Last (time)
    4:00p ET 09/25/23
  • Last (size)
    1
  • 52-Wk Range
    1.30 - 2.97
    LowHigh
  • (09/23/22 - 09/25/23)
    2.31%
  • 80.1%
  • Market Cap
    49.0M
  • Shares Outstanding
    36.8M
  • -1.01
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 2.1
  • 67.92
  • (% of float 08/31/23)
    1.20

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.